Abliva AB Interim Report January – June 2023
The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Press releases
Abliva presents at UMDF Mitochondrial Medicine 2023
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present at UMDF’ ...
Abliva announces first patient dosed in the FALCON study
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the first patient has been dosed ...
Abliva presents scientific data at international conference on mitochondrial medicine
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present scientif ...
Abliva AB Interim Report January – March 2023
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 5, 2023, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023
The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee’s proposal for the election of Board members was [&h ...
Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the drug candidate NV354 has ...
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Friday, 5 May 2023 at Medicon Village, Scheeletorget ...
Abliva AB Publishes 2022 Annual Report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
BioStock Investor Meeting with Abliva
Do not miss Abliva's presentation at the BioStock Investor Meeting, today March 16 at 10.00 am. The event starts at 10.00 - see the full programme on BioStock's website or YouTube channel.
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolutions follows.